APA (7th ed.) Citation

Michael S. Chang, M., Jordan T. Said, M., Elliot H. Akama-Garren, P., Nicole Trepanowski, M., Ai-Tram N. Bui, M., Anita Giobbie-Hurder, M., . . . Rebecca I. Hartman, M. NRAS tumor mutations are associated with reduced odds of dermatologic adverse events in patients with metastatic melanoma receiving immune checkpoint inhibitors. Elsevier.

Chicago Style (17th ed.) Citation

Michael S. Chang, MD, MD Jordan T. Said, PhD Elliot H. Akama-Garren, MD Nicole Trepanowski, MD Ai-Tram N. Bui, MS Anita Giobbie-Hurder, MD Nicole R. LeBoeuf, and MD Rebecca I. Hartman. NRAS Tumor Mutations Are Associated with Reduced Odds of Dermatologic Adverse Events in Patients with Metastatic Melanoma Receiving Immune Checkpoint Inhibitors. Elsevier.

MLA (9th ed.) Citation

Michael S. Chang, MD, et al. NRAS Tumor Mutations Are Associated with Reduced Odds of Dermatologic Adverse Events in Patients with Metastatic Melanoma Receiving Immune Checkpoint Inhibitors. Elsevier.